Loading company…
Qli5 Therapeutics develops proteasome inhibitors for cancer and other potential indications.
Based in Dortmund, Germany, Qli5 Therapeutics develops selective, non-covalent proteasome inhibitors with activity against multiple myeloma and solid tumors. Co-founded by Prof. Robert Huber and Kiyean Nam, the company was led by CEO Martin Huber as of 2023. In June 2022, it raised EUR 10 million in Series A funding from returning investor Khanu Management and new investor Atinum Investment, valuing the company at EUR 86.14 million post-money.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in